Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Gains from Investment Securities (2016 - 2024)

Spyre Therapeutics (SYRE) has disclosed Gains from Investment Securities for 10 consecutive years, with -$200000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Gains from Investment Securities rose 73.3% year-over-year to -$200000.0, compared with a TTM value of -$200000.0 through Dec 2024, up 73.68%, and an annual FY2023 reading of -$15000.0, changed N/A over the prior year.
  • Gains from Investment Securities was -$200000.0 for Q2 2024 at Spyre Therapeutics, down from $3000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $429000.0 in Q2 2022 and bottomed at -$749000.0 in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $9000.0, with a median of $1000.0 recorded in 2020.
  • The sharpest move saw Gains from Investment Securities skyrocketed 34600.0% in 2021, then plummeted 274.59% in 2023.
  • Year by year, Gains from Investment Securities stood at -$14000.0 in 2020, then skyrocketed by 1307.14% to $169000.0 in 2021, then tumbled by 104.14% to -$7000.0 in 2022, then skyrocketed by 142.86% to $3000.0 in 2023, then crashed by 6766.67% to -$200000.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for SYRE at -$200000.0 in Q2 2024, $3000.0 in Q4 2023, and -$12000.0 in Q3 2023.